[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367977-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367977-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","in-vitro-repositioning-therapy-with-olaparib-temozolomide-and-oxaliplatin-in-glioblastoma-cell-lines-study","In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines - Study","","Central nervous system tumors, especially glioblastoma multiforme (GBM), remain among the most aggressive cancers with high lethality. This study evaluates a multidrug repositioning strategy for GBM cell lines by combining temozolomide (TMZ) with olaparib (OLA) and oxaliplatin (OXA), repurposed from other cancer indications. Four GBM cell lines (U118 MG, H4, U251 MG, U87 MG) and human fibroblasts were treated for 72 h to assess viability, IC50 values, and apoptosis/necrosis outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/in-vitro-repositioning-therapy-with-olaparib-temozolomide-and-oxaliplatin-in-glioblastoma-cell-lines-study/367977/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/in-vitro-repositioning-therapy-with-olaparib-temozolomide-and-oxaliplatin-in-glioblastoma-cell-lines-study/367977.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research focus of the study?","Question",{"text":63,"@type":64},"The study investigates whether a multidrug repositioning chemotherapy approach can improve treatment effects against glioblastoma by combining TMZ with OLA and OXA in vitro.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cell lines and concentrations were used in the experiments?",{"text":68,"@type":64},"Glioblastoma cell lines U118 MG, H4, U251 MG, and U87 MG were treated for 72 h with OXA (50–200 µM), OLA (1–100 µM), or TMZ (10–100 µM), with human fibroblasts as a control.",{"name":70,"@type":61,"acceptedAnswer":71},"How was cell viability and cell death assessed?",{"text":72,"@type":64},"Cell viability was measured using an MTS assay and IC50 values were calculated with GraphPad Prism 8. The type of cell death was analyzed using a fluorescence-based Apoptotic, Necrotic & Healthy Cells Quantification Kit.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367977,1790637105,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Pharmacological Reports (2025) 77:1716–1726  \n[https://doi.org/10.1007/s43440-025-00783-w](https://doi.org/10.1007/s43440-025-00783-w)  \nRESEARCH  \nIn vitro repositioning therapy with olaparib, temozolomide andoxaliplatin in glioblastoma cell lines: U118, U87, U251, H4 and human fibroblasts  \nAnna Zając-Grabiec5 · Anna Czopek1 · Karolina Pazdan1 · Jakub Jończyk1 · Filip Michałkiewicz2 · Tomasz Skóra3 · Monika Krzyżowska5 · Beata Biesaga5 · Dominik Wiśniewski4 · Paula Ajersch5 · Justyna Miszczyk5  \nReceived: 24 April 2025 / Revised: 27 August 2025 / Accepted: 28 August 2025 / Published online: 3 September 2025 © The Author(s) 2025  \nAbstract  \nBackground Central nervous system (CNS) tumors, including gliomas, are among the most aggressive cancers, with glioblastoma multiforme (GBM) being the most common and lethal. This study explores the potential of multidrug repositioning as a modern chemotherapy strategy for GBM cell lines. It combines the standard GBM chemotherapeutic temozolomide (TMZ) with olaparib (OLA) and oxaliplatin (OXA), both repurposed from other cancer types. Most experimental drug therapy studies focus on just one or two selected high-grade GBM cell lines, but in this study, four such cell lines were used. Methods Glioblastoma (GBM) cell lines U118 MG, H4, U251 MG and U87 MG were treated for 72 h with oxaliplatin (OXA, 50–200 µM), olaparib (OLA, 1–100 µM), or temozolomide (TMZ, 10–100 µM). Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium (MTS) assay. Half-maximal inhibitory concentration (IC₅₀) values were calculated using GraphPad Prism 8. A human fibroblast line (hFib) from a healthy donor was used as a control. The type of cell death following the above treatments was analysed using a fluorescence-based Apoptotic, Necrotic & Healthy Cells Quantification Kit.  \nResults The combination of OLA, OXA, and TMZ significantly reduced cell viability and survival, inducing apoptosis/ necrosis more effectively than TMZ alone. These synergistic effects alter glioblastoma metabolism, promote apoptosis, and enhance antitumor activity in vitro.  \nConclusions The proposed multidrug repositioning chemotherapy produced a therapeutic effect at lower doses, suggesting that it is potentially a safer and more effective treatment option.  \nKeywords Olaparib · Oxaliplatin · Temozolomide · Glioblastoma multiforme · Multidrug repositioning  \n􀀍 Anna Zając-Grabiec [anna.zajac-grabiec@ifj.edu.pl](anna.zajac-grabiec@ifj.edu.pl)  \n􀀍 Anna Czopek [anna.czopek@uj.edu.pl](anna.czopek@uj.edu.pl)  \n1 Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland  \n2 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, Kraków 30-387, Poland  \n3 Maria Skłodowska-Curie National Research Institute of Oncology, Garncarska 11, Kraków 31-115, Poland  \n4 Wroclaw University of Science and Technology, Wybrzeże Stanisława Wyspiańskiego 27, Wrocław 50-370, Poland  \n5 Department of Medical Physics, Cyclotron Centre Bronowice, Institute of Nuclear Physics, Polish Academy of Sciences, Radzikowskiego 152, Kraków 31-342, Poland  \nAbbreviations  \nAD Adenine–ribose  \nART ADP–ribosyltransferase BER Base excision repair  \nBRCA Associated breast and ovarian cancers CDI Carbonyl diimidazole  \nCHK1 Checkpoint kinase 1  \nCNS Central nervous system CRC Colorectal cancer  \nDCC N,N’–dicyclohexylcarbodiimide DCM Dichloromethane  \nDIC N,N’–diisopropylcarbodiimide DMF Dimethylformamide  \nDMSO Dimethyl sulfoxide DSBs Double–strand breaks GBM Glioblastoma multiforme GSCs Glioma stem–like cells  \nHATU Hexafluorophosphate azabenzotriazole tetramethyl uronium  \nHBTU O–benzotriazole–N,N,N’,N’–tetramethyl– uronium–hexafluoro–phosphate  \nHCL Hydrochloric acid HD Helical  \nhFib Human fibroblast line  \nHPLC High–performance liquid chromatography HRD Homologous recombination deficiency IC50 Half maxi","cbCaiulkPjYOtDH6","https://ap.wps.com/l/cbCaiulkPjYOtDH6","pdf",2764190,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## GBM treatment challenges and resistance\n## Role of glioma stem-like cells and DNA repair","[{\"question\":\"What is the main research focus of the study?\",\"answer\":\"The study investigates whether a multidrug repositioning chemotherapy approach can improve treatment effects against glioblastoma by combining TMZ with OLA and OXA in vitro.\"},{\"question\":\"Which cell lines and concentrations were used in the experiments?\",\"answer\":\"Glioblastoma cell lines U118 MG, H4, U251 MG, and U87 MG were treated for 72 h with OXA (50–200 µM), OLA (1–100 µM), or TMZ (10–100 µM), with human fibroblasts as a control.\"},{\"question\":\"How was cell viability and cell death assessed?\",\"answer\":\"Cell viability was measured using an MTS assay and IC50 values were calculated with GraphPad Prism 8. The type of cell death was analyzed using a fluorescence-based Apoptotic, Necrotic \\u0026 Healthy Cells Quantification Kit.\"}]","In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines - Study | PDF",1790174078,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87f175197216f32d49f4ab1409c96d13.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfd5c4ad2678408b431ef8c582a5aa22.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/205832557679cdde4f636a68c1ae286d.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4d96150e55c91085dbb8ce6ab6bb28f.webp",980,1301]